Dear Reader,
Elon Musk’s “AI Everywhere” project isn’t inside Tesla—it’s a private venture with a global network of 150+ facilities embedding autonomous AI into devices everywhere.
Musk believes this could propel Tesla to become the most valuable company ever, worth more than Apple, Microsoft, Nvidia, Amazon, and Google combined.
Private ventures like this are usually locked for elites, but I’ve found a legitimate brokerage backdoor—under $100, no special requirements, just a regular account.
Musk’s history proves he turns underdogs into giants:
- PayPal → Peter Thiel turned $1,700 into $55 million.
- SpaceX → valuation up 349,900% ($1,000 now worth over $3.4 million).
- Tesla → 22,000%+ since IPO ($1,000 to over $220,000).
- xAI → $0 to $230 billion in under two years.
This private play follows the same playbook—using Tesla’s proven autonomous AI “copy-pasted” across the world.
Watch my full video—I explain the story and give you 3 steps to profit, including how to claim that backdoor stake before the summer regulatory shift.
Here’s to the future,
Matt McCall
P.S. Ignore this and you could miss the biggest Musk-driven opportunity since Tesla’s early days.
Ollie's Stock Won't Stay a Bargain Much Longer
Authored by Thomas Hughes. Article Posted: 3/15/2026.
Key Points
- Ollie's Bargain Outlet posted strong revenue growth in Q4 despite slim misses on earnings and guidance, with both comp-store sales and store expansion outpacing expectations.
- The Big Lots bankruptcy is creating a customer conversion opportunity that analysts believe has years left to play out—and isn't yet reflected in the stock price.
- Institutional investors own nearly all of the float and have been steady buyers, backing a company that funds its own growth and trades below every analyst's target.
- Special Report: Have $500? Invest in Elon's AI Masterplan
Ollie’s Bargain Outlet's (NASDAQ: OLLI) downtrend appears to be over. The Q4 2025 results are in and reaffirm a robust outlook. While the report and guidance came in slightly below consensus, the misses were modest, growth remains healthy, and the weakness was not as unexpected as some investors feared.
Analysts at RBC issued cautious commentary ahead of the release while emphasizing the company’s strong positioning, aggressive expansion plans, and potential to outperform in the coming years. RBC noted that the Big Lots bankruptcy and subsequent customer conversion to Ollie’s are multi-year opportunities that are not fully reflected in the stock price.
Ollie’s Outperforms Peers as Expansion Takes Hold
3-day warning (Ad)
I've worked for the CIA, personally met four US presidents, and spent 45 years studying the markets—calling Black Monday six weeks before it happened, predicting the fall of the Berlin Wall, and pinpointing the exact bottom in 2009. But what I'm about to share with you is the boldest prediction of my career.
After meeting Elon Musk face-to-face at a private gathering of Wall Street elites and months of my own research, I'm now staking my reputation on one date: March 26, 2026. That's when I believe Elon will announce the SpaceX IPO—what Bloomberg is calling the biggest listing of all time. I have found an access code that lets you grab a pre-IPO stake before it happens, but in 72 hours, your window could close.
Click here to see how to claim your SpaceX access codeOllie’s delivered a solid quarter despite revenue growth slightly missing the consensus. Net revenue of $779.26 million was up 16.8% year-over-year—well ahead of many competitors—driven by better-than-expected comps and strong store-count growth. Comparable sales rose 3.6%, a touch above RBC’s forecast, while store count grew 15.4%.
Margins held up reasonably well, as spending discipline and revenue leverage helped offset costs related to new store openings. Adjusted EPS missed the consensus by two cents, but the shortfall was minor, and earnings growth modestly outpaced revenue growth. As opening-related expenses normalize over the next two to three years, there should be clearer visibility into improving margin and earnings quality.
Guidance was slightly below MarketBeat’s reported consensus but still implies solid growth. The company expects full-year revenue of $2.985 billion to $3.013 billion (midpoint slightly under the $3.0 billion consensus) and an EPS midpoint of $4.45 versus $4.53 expected—roughly a 10% top-line increase versus the prior year.
Conservative Guidance Could Kick Off a Bullish Revision Cycle
One potential upside for investors is that management’s guidance may be conservative. Last year the company grew store count by 15.4%, and it plans roughly another 11.6% increase this year. Analysts also point to possible consumer tailwinds tied to tax season: average customer transactions are more than 10% larger than a year ago, giving shoppers additional liquidity to spend at Ollie’s. If the company outperforms its guidance, analysts could revise estimates upward, sparking a bullish cycle.
Ollie’s carries a Moderate Buy consensus rating with no Sell ratings among the 16 analysts tracked by MarketBeat. No immediate estimate revisions followed the Q4 release, but several analysts commented on the growth potential and strength in loyalty members (up 12.1%) while noting the risk of tougher year-over-year comparisons. Not everyone is convinced about the long-term impact of the Big Lots conversion, but the analyst group is generally bullish on the stock, forecasting an average upside near 30%. In early March, Ollie’s trades below the low end of the analysts' range, highlighting a deep-value opportunity and potential for a rebound.
Institutional ownership further underscores the opportunity: institutions hold the vast majority of the shares and tend to add on a quarterly basis. Their reasons for holding include a fortress-like balance sheet, self-funded growth, positive cash flow, and an attractive growth outlook. Capital-return potential adds another layer to the investment case.
The company does not pay a cash dividend, preferring to reinvest in the business, but it does repurchase shares at a pace sufficient to offset dilution. The reduction in share count has been incremental but meaningful, providing a foundation for future per-share gains. Competitors and industry leaders such as TJX Companies (NYSE: TJX) are long-standing dividend and buyback leaders; Ollie’s appears to be moving toward that profile.
Stock Price Bounces From Rock Bottom
Ollie’s stock hit a low late in 2025, bounced, and then retested that level in early 2026. After the guidance update, shares rallied more than 5%, confirming support at this important price level. That level was resistance in 2019, was breached in early 2025, and now appears to be acting as a solid support—a bullish technical development. The likely outcome is continued upward momentum through 2026, with the potential for acceleration as the year progresses.
The Aging of America Could Make HCA Healthcare a Long-Term Winner
Submitted by Nathan Reiff. Published: 3/8/2026.
Key Points
- HCA Healthcare has strong earnings growth, volume gains, and adjusted EBITDA gains, among other metrics, revealing strong fundamentals despite coming up short of analyst revenue estimates last quarter.
- The company's 2026 guidance suggests room to grow in several areas, though threats remain.
- HCA's recent rally may leave little room for short-term growth, but the stock could appeal to investors with longer-term healthcare demand trends in mind.
- Special Report: Have $500? Invest in Elon's AI Masterplan
Shifting demographics in the United States mean adults at retirement age or older will outnumber minors sometime in the coming decade. That growing population will drive substantial healthcare spending, creating a significant opportunity for investors. Because the trend unfolds over many years, it will primarily reward long-term investors.
HCA Healthcare (NYSE: HCA) stands to be a primary beneficiary of this shift thanks to its large network of facilities, including hospitals, ambulatory surgery centers, urgent-care locations and other outpatient sites. The company is already seeing strong demand and utilization, and investors with a longer time horizon may increasingly view HCA as a compelling buy.
A Mixed Earnings Report Masks Fundamental Strengths
3-day warning (Ad)
I've worked for the CIA, personally met four US presidents, and spent 45 years studying the markets—calling Black Monday six weeks before it happened, predicting the fall of the Berlin Wall, and pinpointing the exact bottom in 2009. But what I'm about to share with you is the boldest prediction of my career.
After meeting Elon Musk face-to-face at a private gathering of Wall Street elites and months of my own research, I'm now staking my reputation on one date: March 26, 2026. That's when I believe Elon will announce the SpaceX IPO—what Bloomberg is calling the biggest listing of all time. I have found an access code that lets you grab a pre-IPO stake before it happens, but in 72 hours, your window could close.
Click here to see how to claim your SpaceX access codeHCA's latest earnings report for Q4 2025, as with many healthcare companies, was mixed. The firm comfortably beat analyst expectations for earnings per share (EPS), reporting $8.01—an improvement of nearly 29% versus a forecast of $7.37. Revenue growth of 6.7% year-over-year (YOY), however, was more modest than expected; analysts had forecast quarterly revenue of $19.7 billion, and the company missed that estimate by roughly $158 million.
The slower revenue momentum reflected policy headwinds, the expiration of premium tax credits and shifts in uninsured rates. Still, HCA's results highlight important underlying strengths: the company reported its 19th consecutive quarter of volume growth, adjusted EBITDA rose 11% YOY, and adjusted EBITDA margin expanded by 80 basis points. Patients used HCA's facilities at a record pace—about 47 million patient encounters—which helped operating cash flow improve by 20% for 2025 as a whole.
Signs of Potential From HCA's Guidance
HCA's forward guidance may appeal to potential investors. For 2026, management expects revenue between $76.5 billion and $80 billion, adjusted EBITDA of $15.55 billion to $16.45 billion, and diluted EPS of $29.10 to $31.50.
The company also raised its capital plans, budgeting as much as $5.5 billion in capital expenditures (CapEx) while unveiling a $10 billion share repurchase program. Current shareholders received a higher payout as well: HCA lifted its quarterly dividend by 8.3% to $0.78, yielding about 0.54% with a dividend payout ratio near 10.15%.
Management is forecasting continued improvement in admissions: same-facility admissions rose 2.4% YOY in the quarter, and same-facility revenue per equivalent admission increased 2.9%. For 2026, the company expects equivalent admissions to climb 2% to 3%.
The Risks Remaining For HCA
HCA's momentum does not eliminate risks. Management foresees an adverse impact to adjusted EBITDA in 2026 of $600 million to $900 million due to changes in health insurance exchanges. State supplemental payments could also weigh on results, with expected declines in supplemental net benefits of $250 million to $450 million for the year.
To mitigate some of these pressures, HCA launched a $400 million resiliency program focused on revenue integrity, capacity management and cost discipline through AI and digital investments. The effectiveness of these measures remains to be seen.
Wall Street is generally optimistic about HCA's ability to navigate challenging external forces. Analysts expect earnings to rise more than 12% next year, and roughly two-thirds of the 25 analysts covering HCA rate the shares a Buy or equivalent. Several analysts have already raised price targets or reiterated bullish ratings in 2026.
With nearly 14% year-to-date capital appreciation so far in 2026, HCA's near-term upside may be limited. Still, as the company prepares to serve the anticipated surge in healthcare demand, it could represent an attractive long-term investment.
to bring you the latest market-moving news.
This message is a sponsored email sent on behalf of NXT Wave Research, a third-party advertiser of TickerReport and MarketBeat.
Contact Us | Unsubscribe
© 2006-2026 MarketBeat Media, LLC dba TickerReport.
345 North Reid Place, Sixth Floor, Sioux Falls, SD 57103-7078. USA..
0 Response to "Elon’s Private AI Empire: The Backdoor Under $100"
Post a Comment